Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model.

Area of Science:

• Neuroimmunology
• Animal models of disease
• Multiple Sclerosis research

Background:

• Relapsing multiple sclerosis (MS) treatments have advanced, but effective therapies for non-relapsing progressive MS remain an unmet clinical need.
• Experimental autoimmune encephalomyelitis (EAE) in animal models is crucial for understanding MS mechanisms and developing therapeutics.
• The myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 (MOG^35-55)-induced EAE in nonobese diabetic (NOD) mice has been proposed as a model for secondary progressive MS.

Purpose of the Study:

• To critically evaluate the validity of MOG^35-55-induced EAE in NOD mice as a model for progressive multiple sclerosis.
• To determine if existing data supports the claim that this model accurately reflects the human condition.

Main Methods:

• Induction and clinical monitoring of EAE in NOD mice.
• Comprehensive literature review of relevant studies and data interpretation.

Main Results:

• The NOD mouse model exhibits an asynchronous, relapsing-remitting neurodegenerative disease, not a true progressive course.
• Observed "progressive" trends in group clinical scores are artifacts of data aggregation and interpretation.
• The model's individual disease courses show poor recovery from relapses, not steady decline.

Conclusions:

• MOG^35-55-induced EAE in NOD mice lacks validity as a progressive multiple sclerosis model.
• This model should not be used to justify clinical trials for non-active, progressive MS.
• Transparent raw data deposition in animal studies is essential for validating translational research in MS.